Skip to main content

Use of newer antifungal therapies in clinical practice: what do the data tell us?

Publication ,  Journal Article
Perfect, JR
Published in: Oncology (Williston Park)
November 2004

Considering the significant morbidity and mortality associated with invasive fungal infections in immunocompromised patients, it is particularly important to make the diagnosis as early as possible and to make best use of the available antifungal drugs for prophylaxis and treatment. The newer antifungal drugs include the lipid products of amphotericin B, such as amphotericin B lipid complex (ABLC) and liposomal amphotericin B; voriconazole (a triazole); and caspofungin (an echinocandin). ABLC and liposomal amphotericin B are as effective as amphotericin B deoxycholate but are less nephrotoxic; ABLC is probably the drug of choice for zygomycosis. Voriconazole is approved for use in the treatment of invasive aspergillosis and may have a role in preventing breakthrough fungal infections in patients with persistent fever and neutropenia. Caspofungin is effective against both invasive aspergillosis and invasive candidiasis.

Duke Scholars

Published In

Oncology (Williston Park)

ISSN

0890-9091

Publication Date

November 2004

Volume

18

Issue

13 Suppl 7

Start / End Page

15 / 23

Location

United States

Related Subject Headings

  • Zygomycosis
  • Voriconazole
  • Triazoles
  • Treatment Outcome
  • Time Factors
  • Randomized Controlled Trials as Topic
  • Pyrimidines
  • Phosphatidylglycerols
  • Phosphatidylcholines
  • Peptides, Cyclic
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Perfect, J. R. (2004). Use of newer antifungal therapies in clinical practice: what do the data tell us? Oncology (Williston Park), 18(13 Suppl 7), 15–23.
Perfect, John R. “Use of newer antifungal therapies in clinical practice: what do the data tell us?Oncology (Williston Park) 18, no. 13 Suppl 7 (November 2004): 15–23.
Perfect JR. Use of newer antifungal therapies in clinical practice: what do the data tell us? Oncology (Williston Park). 2004 Nov;18(13 Suppl 7):15–23.
Perfect, John R. “Use of newer antifungal therapies in clinical practice: what do the data tell us?Oncology (Williston Park), vol. 18, no. 13 Suppl 7, Nov. 2004, pp. 15–23.
Perfect JR. Use of newer antifungal therapies in clinical practice: what do the data tell us? Oncology (Williston Park). 2004 Nov;18(13 Suppl 7):15–23.

Published In

Oncology (Williston Park)

ISSN

0890-9091

Publication Date

November 2004

Volume

18

Issue

13 Suppl 7

Start / End Page

15 / 23

Location

United States

Related Subject Headings

  • Zygomycosis
  • Voriconazole
  • Triazoles
  • Treatment Outcome
  • Time Factors
  • Randomized Controlled Trials as Topic
  • Pyrimidines
  • Phosphatidylglycerols
  • Phosphatidylcholines
  • Peptides, Cyclic